{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:38:50Z","timestamp":1793385530959,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,22]],"date-time":"2027-07-22T00:00:00Z","timestamp":1816214400000},"content-version":"am","delay-in-days":263,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM148403"],"award-info":[{"award-number":["T32GM148403"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018317","name":"Virginia Commonwealth University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA033934"],"award-info":[{"award-number":["P30DA033934"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.neuropharm.2026.111106","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:36:05Z","timestamp":1784129765000},"page":"111106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Respiratory depressant interactions of fentanyl and xylazine and their reversal by naloxone and yohimbine in mice"],"prefix":"10.1016","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0821-1707","authenticated-orcid":false,"given":"Melissa R.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0987-8858","authenticated-orcid":false,"given":"D. Matthew","family":"Walentiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111106_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110993","article-title":"Xylazine potentiates the lethal but not the rewarding effects of fentanyl in mice","volume":"253","author":"Acosta-Mares","year":"2023","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2026.111106_bib2","series-title":"Provisional Drug Overdose Death Counts. [Internet]","author":"Ahmad","year":"2026"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111106_bib3","article-title":"Xylazine in the opioid epidemic: a systematic review of case reports and clinical implications","volume":"15","author":"Ayub","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.neuropharm.2026.111106_bib4","article-title":"Opioids depress breathing through two small brainstem sites","volume":"vol. 9","author":"Bachmutsky","year":"2020"},{"key":"10.1016\/j.neuropharm.2026.111106_bib5","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67523","article-title":"Dual mechanisms of opioid-induced respiratory depression in the inspiratory rhythm-generating network","volume":"10","author":"Baertsch","year":"2021","journal-title":"eLife"},{"issue":"12","key":"10.1016\/j.neuropharm.2026.111106_bib6","first-page":"1170","article-title":"Failure of naloxone to reverse clonidine toxic effect","volume":"137","author":"Banner","year":"1983","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.neuropharm.2026.111106_bib7","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81119","article-title":"Opioid suppression of an excitatory pontomedullary respiratory circuit by convergent mechanisms","volume":"12","author":"Bateman","year":"2023","journal-title":"eLife"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111106_bib8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bph.15580","article-title":"Understanding and countering opioid-induced respiratory depression","volume":"180","author":"Bateman","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111106_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2024.100155","article-title":"Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism","volume":"11","author":"Bedard","year":"2024","journal-title":"Addiction Neuroscience"},{"issue":"12","key":"10.1016\/j.neuropharm.2026.111106_bib10","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1093\/cercor\/bhn040","article-title":"Locus coeruleus \u03b1-Adrenergic\u2013Mediated activation of cortical astrocytes in vivo","volume":"18","author":"Bekar","year":"2008","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2026.111106_bib11","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00213-025-06804-z","article-title":"Xylazine potentiates the interoceptive effects of fentanyl in Male and female rats","volume":"243","author":"Bender","year":"2025","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111106_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12954-024-00959-2","article-title":"Xylazine co-occurrence with illicit fentanyl is a growing threat in the deep south: a retrospective study of decedent data","volume":"21","author":"Bradford","year":"2024","journal-title":"Harm Reduct. J."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111106_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103397","article-title":"Antagonism of the antinociceptive effects of fentanyl and the veterinary anesthetic xylazine in mice","volume":"392","author":"Cakir","year":"2025","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111106_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50630","article-title":"Xylazine in overdose deaths and forensic drug reports in US states, 2019-2022","volume":"7","author":"Cano","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111106_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/archpsyc.1984.01790190025003","article-title":"Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder","volume":"41","author":"Charney","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111106_bib16","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","article-title":"Xylazine effects on opioid-induced brain hypoxia","volume":"240","author":"Choi","year":"2023","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111106_bib17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41386-023-01782-2","article-title":"Combined treatment with naloxone and the alpha2 adrenoceptor antagonist atipamezole reversed brain hypoxia induced by a fentanyl-xylazine mixture in a rat model","volume":"49","author":"Choi","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111106_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103616","article-title":"Xylazine exacerbates fentanyl-induced respiratory depression and bradycardia","volume":"392","author":"Demery","year":"2025","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111106_bib20","first-page":"517","article-title":"Cardiopulmonary effects of xylazine and yohimbine in laterally recumbent sheep","volume":"50","author":"Doherty","year":"1986","journal-title":"Can. J. Vet. Res."},{"key":"10.1016\/j.neuropharm.2026.111106_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109740","article-title":"Amphetamines modulate fentanyl-depressed respiration in a bidirectional manner","volume":"243","author":"Elder","year":"2023","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2026.111106_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173601","article-title":"Theophylline reverses oxycodone's but not fentanyl's respiratory depression in mice while caffeine is ineffective against both opioids","volume":"229","author":"Elder","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2026.111106_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173735","article-title":"Enantiomeric contributions to methamphetamine's bidirectional effects on basal and fentanyl-depressed respiration in mice","volume":"238","author":"Elder","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2026.111106_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111106_bib25","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0035-23.2023","article-title":"Fentanyl-induced respiratory depression and locomotor hyperactivity are mediated by \u03bc-Opioid receptors expressed in somatostatin-negative neurons","volume":"10","author":"Furdui","year":"2023","journal-title":"eNeuro"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111106_bib26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/bja\/aem011","article-title":"The \u03b12-adrenergic receptor antagonist yohimbine improves endotoxin-induced inhibition of gastrointestinal motility in mice","volume":"98","author":"Hamano","year":"2007","journal-title":"Br. J. Anaesth."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111106_bib27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1152\/japplphysiol.00819.2021","article-title":"Effects of fentanyl overdose-induced muscle rigidity and dexmedetomidine on respiratory mechanics and pulmonary gas exchange in sedated rats","volume":"132","author":"Haouzi","year":"2022","journal-title":"J. Appl. Physiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111106_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/15563650.2024.2309326","article-title":"Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities","volume":"62","author":"Hays","year":"2024","journal-title":"Clin. Toxicol."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111106_bib29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/npp.2015.201","article-title":"Ethanol reversal of tolerance to the respiratory depressant effects of morphine","volume":"41","author":"Hill","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"24","key":"10.1016\/j.neuropharm.2026.111106_bib31","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1111\/bph.16199","article-title":"Assessment of the potential of novel and classical opioids to induce respiratory depression in mice","volume":"180","author":"Hill","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111106_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bph.14860","article-title":"Fentanyl depression of respiration: Comparison with heroin and morphine","volume":"177","author":"Hill","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111106_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0572","article-title":"Knowledge, preference, and adverse effects of xylazine among adults in substance use treatment","volume":"7","author":"Hochheimer","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111106_bib33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.5498\/wjp.v14.i6.760","article-title":"Fentanyl and xylazine crisis: crafting coherent strategies for opioid overdose prevention","volume":"14","author":"Jain","year":"2024","journal-title":"World J. Psychiatr."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111106_bib34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41386-019-0368-x","article-title":"Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects","volume":"44","author":"Johansson","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111106_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","article-title":"Increasing presence of xylazine in heroin And\/Or fentanyl deaths, Philadelphia, Pennsylvania, 2010\u20132019","volume":"27","author":"Johnson","year":"2021","journal-title":"Inj. Prev."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111106_bib36","doi-asserted-by":"crossref","first-page":"R408","DOI":"10.1152\/ajpregu.00238.2024","article-title":"Life-threatening fentanyl overdose beyond medullary depression in breathing","volume":"328","author":"Judenherc-Haouzi","year":"2025","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"26","key":"10.1016\/j.neuropharm.2026.111106_bib37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine\u2014United states, January 2019\u2013June 2022","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111106_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1037\/pha0000670","article-title":"Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats","volume":"32","author":"Khatri","year":"2024","journal-title":"Exp. Clin. Psychopharmacol"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111106_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvp.12724","article-title":"The \u03b12A-adrenoceptor subtype plays a key role in the analgesic and sedative effects of xylazine","volume":"42","author":"Kitano","year":"2019","journal-title":"J. Vet. Pharmacol. Therapeut."},{"issue":"19","key":"10.1016\/j.neuropharm.2026.111106_bib40","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1113\/JP270822","article-title":"\u03bc opioid receptor activation hyperpolarizes respiratory-controlling k\u00f6lliker\u2013fuse neurons and suppresses post-inspiratory drive","volume":"593","author":"Levitt","year":"2015","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2026.111106_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108974","article-title":"Fentanyl causes naloxone-resistant vocal cord closure: a platform for testing opioid overdose treatments","volume":"227","author":"Miner","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111106_bib42","article-title":"The management of xylazine overdose with naloxone","volume":"16","author":"Morris","year":"2024","journal-title":"Cureus"},{"issue":"23","key":"10.1016\/j.neuropharm.2026.111106_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312856","article-title":"Multifaced nature of yohimbine\u2014A promising therapeutic potential or a risk?","volume":"25","author":"Nowacka","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111106_bib44","series-title":"StatPearls [Internet]","article-title":"Xylazine toxicity","author":"Papudesi","year":"2025"},{"key":"10.1016\/j.neuropharm.2026.111106_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2024.100247","article-title":"Xylazine awareness, desire, use and exposure: preliminary findings from the Rhode Island community-based drug checking cohort study","volume":"11","author":"Park","year":"2024","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111106_bib46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40262-024-01355-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of naloxone","volume":"63","author":"Saari","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2026.111106_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109816","article-title":"Impacts of xylazine on fentanyl demand, body weight, and acute withdrawal in rats: a comparison to lofexidine","volume":"245","author":"Sadek","year":"2024","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111106_bib48","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/15563650.2018.1450986","article-title":"Naloxone reversal of clonidine toxicity: dose, dose, dose","volume":"56","author":"Seger","year":"2018","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2026.111106_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2024.104527","article-title":"Targeting \u03b11- and \u03b12-adrenergic receptors as a countermeasure for fentanyl-induced locomotor and ventilatory depression","volume":"110","author":"Shaykin","year":"2024","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111106_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1280289","article-title":"\u201cTranq-dope\u201d overdose and mortality: lethality induced by fentanyl and xylazine","volume":"14","author":"Smith","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111106_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2460\/ajvr.68.1.20","article-title":"Anesthesia induced by administration of xylazine hydrochloride alone or in combination with ketamine hydrochloride and reversal by administration of yohimbine hydrochloride in captive axis deer (axis axis)","volume":"68","author":"Sontakke","year":"2007","journal-title":"Am. J. Vet. Res."},{"issue":"30","key":"10.1016\/j.neuropharm.2026.111106_bib52","article-title":"Drug overdose deaths involving xylazine: united States, 2018\u20132021","author":"Spencer","year":"2023","journal-title":"Vital Statistics Rapid Release"},{"key":"10.1016\/j.neuropharm.2026.111106_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111282","article-title":"Xylazine does not enhance fentanyl reinforcement in rats: a behavioral economic analysis","volume":"258","author":"St Onge","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2026.111106_bib54","article-title":"Opioids modulate an emergent rhythmogenic process to depress breathing","volume":"vol. 8","author":"Sun","year":"2019"},{"key":"10.1016\/j.neuropharm.2026.111106_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124059","article-title":"A quantitative LC-MS\/MS analysis of xylazine, p-Fluorofentanyl, fentanyl and fentanyl-related compounds in postmortem blood","volume":"1237","author":"Truver","year":"2024","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111106_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1113\/JP278612","article-title":"Differential impact of two critical respiratory centers in opioid-induced respiratory depression in awake mice","volume":"598","author":"Varga","year":"2020","journal-title":"J Physiol."},{"key":"10.1016\/j.neuropharm.2026.111106_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114805","article-title":"Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated","volume":"195","author":"Varshneya","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111106_bib58","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.psyneuen.2011.03.019","article-title":"Naloxone-induced cortisol predicts mu opioid receptor binding potential in specific brain regions of healthy subjects","volume":"36","author":"Wand","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2026.111106_bib59","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-026-07031-w","article-title":"Xylazine exacerbates fentanyl-induced respiratory depression and prevents rescue by naloxone in mice","author":"Watkins","year":"2026","journal-title":"Psychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:25:59Z","timestamp":1786076759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826002807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":58,"alternative-id":["S0028390826002807"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111106","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Respiratory depressant interactions of fentanyl and xylazine and their reversal by naloxone and yohimbine in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111106"}}